Roundtable Discussion: Transcriptomic & Biomarker Strategies for Navigating Residual Risk (Separating Responders & Non-Responders & Determining Combination Therapy Success) in CKD
- Mapping patient biology with transcriptomics and panels of biomarkers to identify gaps in disease mechanisms that aren’t being rescued/treated by current drugs in the landscape
- Translating these gaps in biology to identify molecular and clinical markers that distinguish responders from non-responders to existing therapies
- Evaluate potential benefits and risks of combination regimens (e.g., SGLT2 + GLP-1) based on patient phenotype